$0.41
1.27% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Aptose Biosciences Inc. Stock price

$0.41
+0.02 3.90% 1M
-1.09 72.99% 6M
-2.13 84.05% YTD
-2.52 86.17% 1Y
-37.09 98.92% 3Y
-33.64 98.81% 5Y
-86.17 99.53% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.01 1.27%
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Key metrics

Market capitalization $7.25m
Enterprise Value $-260.00k
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-40.91m
Cash position $8.33m
EPS (TTM) EPS $-4.43
P/E forward negative
Short interest 0.88%
Show more

Is Aptose Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Aptose Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

Buy
100%

Financial data from Aptose Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.45 0.45
8% 8%
-
-0.45 -0.45
8% 8%
-
- Selling and Administrative Expenses 12 12
23% 23%
-
- Research and Development Expense 28 28
14% 14%
-
-40 -40
17% 17%
-
- Depreciation and Amortization 0.45 0.45
8% 8%
-
EBIT (Operating Income) EBIT -41 -41
16% 16%
-
Net Profit -40 -40
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptose Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptose Biosciences Inc. Stock News

Neutral
GlobeNewsWire
22 days ago
SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), announced the voting results from its special meeting of shareholders held today, S...
Neutral
GlobeNewsWire
28 days ago
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the "Meeting") convened on August 15, 2024, at 1:00 p.m. (ET) has been ...
More Aptose Biosciences Inc. News

Company Profile

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Head office Canada
CEO William Rice
Employees 35
Founded 1986
Website www.aptose.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today